Results of a 5 Years Prospective Study of Estriol Succinate Treatment in Patients with Climacteric Complaints

Abstract

In a prospective study 911 patients were treated over a period of 5 years (M = 2.2) or a total of 2007 treatment years with estriol succinate oral (Synapause, 2-12 mg per day). The treatment was very effective in the removal of all typical climacteric complaints and of the atrophic genital changes caused by estrogen deficiency. Subjective side effects were seldom seen and without practical importance for the treatment. Objective, grave side effects were only few: one superficial phlebo-thrombosis, 2 cases of thrombophlebitis, one carcinoma in situ of the portio vaginalis uteri and 2 mammary cancers were seen. The carcinoma had probably no causal relationship to the treatment. Embolies, myocardial infarctions, cerebrovascular and liver-gall bladder complications did not occur during treatment. The rate of uterine bleedings was low. The incidence of all complications was not increased by estriol succinate; but was even lower than expected. Endometrial and ovarian cancers were not seen. Estriol succinate is accordingly a very effective and well tolerated preparation against climacteric complaints, exerting no significant side effects. It is remarkable that it does not proliferate the endometrium when given in one dose a day. Estriol succinate can therefore be characterized as the estrogen to be favoured for the treatment of postclimacteric women, who do not want to have uterine bleedings any longer.(ABSTRACT TRUNCATED AT 250 WORDS)

Treatment of multiple sclerosis with the pregnancy hormone estriol

“…Consistent with previous reports, 25,26 estriol was well tolerated with only menstrual cycle abnormalities. In three patients, endometrial biopsy was performed to investigate abnormal menstrual bleeding.…”

Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial

“…symptoms over 40 years. [11][12][13] The standard daily dose for menopause symptoms (2 mg) is generally lower than the dose we used, although some studies have used up to 16 mg. In this study, a dose of 8 mg induced an estriol concentration equivalent to that present early in the second trimester of pregnancy, consistent with previous fi ndings.…”

“…[7][8][9] Estriol has been used for several decades throughout Europe and Asia for treating menopausal symptoms. [11][12][13] A Women's Health Initiative study 14 done in 2002 to assess whether premarin (a complex mix of conjugated oestrogens) protects against coronary heart disease in menopausal women aged 50-79 years was stopped prematurely because of an increased risk for cardiovascular disease and breast cancer, whereas the number of colorectal cancers and hip fractures decreased. Premarin includes estradiol, an oestrogen that is present at low concentrations in women with normal menstrual cycles and in oral contraceptives.…”

Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol

“…than benefit in preventative medicine strategies in healthy menopausal women, in whom only minimum to no toxicity is tolerable, the risk/benefit ratio in patients with a chronic autoimmune disease is quite different, with modest toxicity tolerable. The use of pregnancy doses of estriol, the safest of the three estrogens (63)(64)(65), may provide an opportunity to optimize anti-inflammatory efficacy and minimize toxicity.…”